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abstract
PURPOSE Outcomes in RAS-mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited
therapeutic options. Adavosertib is the first small-molecule inhibitor ofWEE1 kinase.We hypothesized that aberrations
in DNA replication seen in mCRC with both RAS and TP53 mutations would sensitize tumors to WEE1 inhibition.
METHODS Patients with newly diagnosed mCRC were registered into FOCUS4 and tested for TP53 and RAS
mutations. Those with both mutations who were stable or responding after 16 weeks of chemotherapy were
randomly assigned 2:1 between adavosertib and active monitoring (AM). Adavosertib (250 mg or 300 mg) was
taken orally once on days 1-5 and days 8-12 of a 3-week cycle. The primary outcome was progression-free
survival (PFS), with a target hazard ratio (HR) of 0.5 and 80% power with a one-sided 0.025 significance level.
RESULTS FOCUS4-C was conducted between April 2017 and Mar 2020 during which time 718 patients were
registered; 247 (34%) were RAS/TP53-mutant. Sixty-nine patients were randomly assigned from 25 UK
hospitals (adavosertib5 44; AM5 25). Adavosertib was associated with a PFS improvement over AM (median
3.61 v 1.87 months; HR5 0.35; 95% CI, 0.18 to 0.68; P5 .0022). Overall survival (OS) was not improved with
adavosertib versus AM (median 14.0 v 12.8months; HR5 0.92; 95% CI, 0.44 to 1.94; P5 .93). In prespecified
subgroup analysis, adavosertib activity was greater in left-sided tumors (HR 5 0.24; 95% CI, 0.11 to 0.51),
versus right-sided (HR 5 1.02; 95% CI, 0.41 to 2.56; interaction P 5 .043). Adavosertib was well-tolerated;
grade 3 toxicities were diarrhea (9%), nausea (5%), and neutropenia (7%).
CONCLUSION In this phase II randomized trial, adavosertib improved PFS compared with AM and demonstrates
potential as a well-tolerated therapy for RAS/TP53-mutant mCRC. Further testing is required in this sizable
population of unmet need.
J Clin Oncol 00. © 2021 by American Society of Clinical Oncology
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INTRODUCTION
Targeting the cellular DNA damage response (DDR)
has been an effective therapeutic strategy in several
tumor sites, including ovarian and pancreatic
cancer.1,2 These agents can be used as monotherapy
in cancers with defective DDR, where we might an-
ticipate a synthetic lethality interaction: two pathways
together perform an essential function, and the loss of
one pathway (eg, because of mutation) is tolerated but
the loss of both pathways leads to cell death.3
WEE1 is a nuclear tyrosine kinase that has a central role
in cell cycle regulation, including being the key regulator
of the G2/M checkpoint through actions on CDK1,4
optimizing DNA-histone stoichiometry before mitotic
entry4 and modulation of CDK1/2 during the intra-S
phase to block replication initiation.5 Inhibition of WEE1
causes unscheduled entry intomitosis, aberrant firing of
replication origins leading to dNTP (Dithiobis [5-nitro-
pyridine]) shortage and replication stress,4 and accu-
mulation of DNA damage during S phase, leading to
increased reliance on the G1/S checkpoint.4 Adavo-
sertib (AZD1775) is the first small-molecule inhibitor of
WEE1 kinase and has been tested in combination with
chemotherapy and radiotherapy6,7 but more recently as
monotherapy to generate synthetic lethality in tumors
with DDR defects.6
There has been limited investigation into agents tar-
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(mCRC), mainly because of the lack of systematic identi-
fication of alterations in DDR genes.8 Here, we test adavosertib
in RAS- and TP53-mutant (RAS/TP53-mut) mCRC, which we
hypothesize would be sensitive to WEE1 inhibition. TP53 is
a key regulator of the G1/S checkpoint9; loss of function leads
to dependence on the intra-S and G2/M checkpoints to detect
DNA damage and initiate repair.10 In preclinical studies,
AZD1775 possessed preferential killing effect in TP53-de-
ficient compared with TP53 wild-type tumors.11 Mutant RAS,
as well as recognized actions through downstream mitogen-
activated protein kinase B (MAPK-AKT) pathway signaling,
also drives cell cycle progression leading to replication stress
during S phase.12 In preclinical studies, mutant RAS drives
cells into S phase through regulation of the CDK4 or CDK6
complex and provides sustained mitogenic signals through
sustained CDK2 activity. These effects activate the replication
stress response including checkpoint activation.13 Theoretically,
RAS/TP53-mut tumors will be highly vulnerable to adavosertib,
with G1 checkpoint failure, evidence of replication stress, and
reliance on the intra-S phase and G2/M checkpoints.
The FOCUS4 trial program was an adaptive molecularly
stratified umbrella platform trial that evaluated the safety
and efficacy of novel treatments in targeted biomarker
subgroups within a phase II/III trial setting in the interval
after 16 weeks of first-line therapy of mCRC. The design has
been published separately,14 and the trial schema, regis-
tration, and biomarker methods are provided in the Data
Supplement (online only). Here, we report the findings of
FOCUS4-C, which tested the safety and efficacy of ada-
vosertib in patients with RAS/TP53-mut mCRC compared
with active monitoring (AM) and has achieved disease
stability following induction chemotherapy.
METHODS
Trial Approvals, Patient Eligibility, and Recruitment
The trial and subsequent amendments were approved by
the UK National Ethics Committee Oxford—Panel C (ref-
erence 13/SC/0111) and by the relevant regulatory body
MHRA (CTA No. 20363/0400/001 and EudraCT No. 2012-
005111-12).
Patients age more than 18 years with newly diagnosed
mCRCwere registered into the FOCUS4 trial program, while
undergoing induction chemotherapy, from a total of 88 UK
hospitals. Following registration, a tumor sample was tested
using next generation sequencing platform for stratification
into molecular subtypes including BRAF, PIK3CA, TP53,
and RAS mutations (Fig 1 and Data Supplement). Patients
were required to provide written informed consent for both
tissue testing and entry into any of the randomized sub-
trials including FOCUS4-C.
Patients were randomly assigned into the FOCUS4-C trial in
a subset of 25 hospitals between July 2017 and March
2020. Patients were eligible if their tumor had bothRAS and
TP53 mutations and they had disease stability or response
as assessed by computed tomography (CT) scan at the end
of 16 weeks of induction chemotherapy, at which point the
chemotherapy ceased and the patient was randomly
assigned. Patients required a baseline CT scan 4 weeks
before random assignment, a minimum 3-week washout
period between the last dose of chemotherapy or biologic
therapy and the first dose of adavosertib, adequate renal
(creatinine clearance . 50 mL/min) and liver function,
a WHO performance status of 0-1, and no evidence of
prolonged QT interval on ECG.
CONTEXT
Key Objective
To test if adavosertib, which is a small-molecule inhibitor of the WEE1 kinase, is effective as monotherapy in patients with
RAS/TP53-mutant metastatic colorectal cancer (mCRC) as maintenance therapy following induction chemotherapy.
Knowledge Generated
In this phase II randomized trial, adavosertib was well-tolerated and improved progression-free survival inRAS/TP53-mutant
mCRC compared with active monitoring. Treatment effect may be affected by primary tumor location and KRAS subtype,
with greater benefit seen in left-sided cancers and those with KRAS codon 12/13 mutations. RAS/TP53 subgroup is
a distinct moderately poor prognostic population.
Relevance
Adavosertib is a promising therapeutic agent in patients with RAS/P53-mutant mCRC, a poor prognostic population of
unmet need, and was well-tolerated. This study demonstrates the potential of targeting the DNA damage response
pathway in mCRC, which should be a research priority. Future studies of adavosertib should stratify patient outcomes
according to primary tumor location and RAS subtype.
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Trial Procedures
Adavosertib was supplied by AstraZeneca Ltd (Cambridge,
UK); packaging, labeling, and distribution were undertaken
by Fisher Services (Horsham, UK). Patients randomly
assigned to adavosertib continued the drug until disease
progression, death, or intolerable toxicity. The first 21 pa-
tients received adavosertib 250 mg once daily, on days 1-5
and 8-12 of a 3-week cycle. The next 23 patients received
Assay preparation
Total registered within date range






Randomly assigned into FOCUS4-N (n = 3)
Not randomly assigned (n = 79), of which
   Patient and clinician decision (n = 37)
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   Unable because of COVID-19 (n = 11)
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FIG 1. Flowchart of patients through the trial. CR, complete response; ITT, intention-to-treat; PPA, per-
protocol analysis; PR, partial response; SD, stable disease.
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adavosertib 300 mg once daily, on the same schedule.
Patients took an oral 5HT3 antagonist with each dose, and
oral dexamethasone 4 mg was given on day 1 and day 8 of
each cycle unless clinically contraindicated.
Because of the mandatory supportive medication for
nausea and vomiting for which a placebo was not available,
blinding was not possible, and AM was used as the control
arm. Patients randomly assigned to AM followed the same
follow-up schedule and remained off any other anticancer
treatment until clinical or radiologic evidence of disease
progression.
Patient tumor status was assessed at the treating hospital
every 8 weeks by CT scan, according to RECIST, version
1.1.15 Toxicities and symptoms were assessed locally every
4 weeks, using the National Cancer Institute’s Common
Terminology Criteria for Adverse Events (version 3.0). Pa-
tients remained on trial until disease progression occurred,
at which point the patient was recommended to restart the
same chemotherapy that was used in the induction phase.
Treatment was stopped in the event of grade 3 or worse
toxic effects or persistent toxicities judged medically sig-
nificant or not tolerated by the patient, until the toxicity
resolved to grade 1 or better.
Statistical Methods
A full description of the statistical methods is provided in the
Data Supplement. In summary, patients were allocated to
either adavosertib or AM, using a 2:1 allocation ratio by
minimization with a 20% random element. All analyses
were performed according to a predefined statistical
analysis plan using Stata (version 16.1; Stata Corporation,
TX). The primary outcome measure was progression-free
survival (PFS), and the prespecified primary efficacy
analysis was a per-protocol analysis (PPA) using Cox re-
gression adjusting for minimization factors. Intention-to-
treat (ITT) and unadjusted models were also performed as
secondary analyses. Sample size calculations were based
upon a target hazard ratio (HR) of 0.5 with 80% power and
.025 one-sided alpha requiring a target of 26 PFS events in
the control arm for final analysis.
RESULTS
Recruitment and Patient Characteristics
The FOCUS4 trial program ran between January 2014 and
March 2020. FOCUS4-C ran between April 2017 and
March 2020, during which time 817 patients were regis-
tered, of whom 718 underwent successful biomarker
profiling (Fig 1 and Data Supplement). Two hundred forty-
seven patients (34%) had tumors confirmed with both RAS
and TP53 mutations (RAS/TP53-mut). Of these, 151 had
stable or responding disease after 16 weeks of first-line
treatment and 69 were randomly assigned using a 2:1 ratio:
44 to adavosertib and 25 to AM. Of the remaining eligible
82, two chose to be randomly assigned into the concurrent
FOCUS4-N trial and others chose not to be randomly
assigned into FOCUS4 for reasons such as toxicity from
first-line therapy or patient-clinician choice to seek alter-
native pathways.
Table 1 summarizes the patient baseline characteristics.
There were some minor imbalances, which are corrected
for in the adjusted analysis (primary model). There were no
differences in the frequency of other molecular alterations
between the groups. There were no significant differences
between the registration period chemotherapy regimens in
the adavosertib and AM arms.
Primary Analysis: PFS (per-protocol)
Five patients were excluded from the PPA: four did not start
treatment (adavosertib arm) and one was subsequently
found to have had progressive disease at the point of
random assignment (AM arm). One patient was censored
early when they received fluorouracil as anticancer treat-
ment before progression (AM arm).
Within the primary PPA (n 5 64), there were 40 of 40 PFS
events in the adavosertib arm and 22 of 24 in the AM arm.
Patients treated with adavosertib had a longer PFS than
those on AM (3.61 v 1.87 months). Both unadjusted HR
(0.52; 95% CI, 0.30 to 0.89; P 5 .022) and adjusted HR
(0.35; 95% CI, 0.18 to 0.68; P 5 .0022) were statistically
significant. Kaplan-Meier curves are provided in Figure 2.
PFS (ITT)
All patients were included in the ITT analysis, but four
patients were censored the day after random assignment:
three in the adavosertib arm (two because of patient
withdrawal and one without any post–random assignment
CT scan assessments) and one in the AM arm without any
post–random assignment CT scan assessments.
There were 41 of 44 PFS events in the adavosertib arm and
23 of 25 in the AM arm. Consistent with the PPA, the ITT
PFS analysis shows a PFS advantage with adavosertib over
AM in both the unadjusted (HR 5 0.55; 95% CI, 0.32 to
0.94; P 5 .032) and adjusted analyses (HR 5 0.40; 95%
CI, 0.21 to 0.75; P 5 .0051).
Overall Survival (ITT)
There were 27 of 44 deaths in the adavosertib arm and 16
of 25 in the AM arm. There was no significant overall
survival (OS) benefit with adavosertib compared with AM
(median survival 14.0 v 12.8 months; unadjusted
HR 5 0.79; 95% CI, 0.42 to 1.48, P 5 .47; adjusted
HR 5 0.92; 95% CI, 0.44 to 1.94, P 5 .93; Fig 2).
Tumor Control
Adavosertib was associated with a higher proportion of
patients with disease control compared with AM (47% v
28% at any time during the trial), including one patient with
a documented partial response to adavosertib (Data
Supplement).
4 © 2021 by American Society of Clinical Oncology
Seligmann et al
Downloaded from ascopubs.org by 31.49.196.212 on September 20, 2021 from 031.049.196.212
Copyright © 2021 American Society of Clinical Oncology. All rights reserved. 
Subgroup Analyses
The impact of adavosertib versus AM on PFS was explored
in prespecified subgroups (Fig 3). The most marked dif-
ference in effect was for primary tumor location (PTL):
patients with a right PTL had no PFS advantage with
adavosertib compared with AM (1.87 v 1.91 months;
HR5 1.02; 95% CI, 0.41 to 2.56), whereas those with a left
PTL did (3.61 v 1.87 months, HR 5 0.24; 95% CI, 0.11 to
0.51; interaction P 5 .043; Data Supplement).
This prompted an unplanned subgroup analysis of PTL on
OS, and although the numbers of events were low, the
interaction was even more marked (Data Supplement).
Median OS was 14.1 versus 11.3 months for adavosertib
versus AM in left PTL (adjusted HR5 0.37; 95% CI, 0.15 to
0.87) but was 6.5 versus 15.5 months in right PTL
(HR5 6.5; 95% CI, 0.72 to 6.43; interaction P5 .0032). In
terms of response, 38% of right-sided adavosertib patients
versus 42% of right-sided AM patients reported disease
stability or response at least once while on trial, whereas for
left-sided tumors, the figures were 53% versus 19%.
Patients who had responded to induction chemotherapy (v
stable disease) and who had two or more metastatic sites
appeared to benefit more from adavosertib, albeit to
a lesser degree (interaction P value 5 .14 for response to
induction; P 5 .12 for number of metastatic sites; Fig 3).
External Analyses to Further Characterize the RAS/TP53-
Mut Biomarker Population
The RAS/TP53-mutant population has not been previously
described. To understand the prognostic implication of this
alteration, we analyzed the outcomes of a subset (n5 438)
of patients from the FOCUS trial in whom the S:CORT
consortium had analyzed a wider panel of CRC genes in-
cluding KRAS, NRAS, BRAF, MSI, and TP53. The RAS/
RAF wild-type group was the reference population (median
OS 21.6 months). The RAS/TP53-mutant population is
distinct from either mutation alone (RAS or TP53) and had
a worse prognosis than either in isolation with a median OS
of 14.9 months (HR 5 2.06; 95% CI, 1.08 to 3.93;
P 5 .028; Fig 4). This suggests that the RAS/TP53-mut
population is a poor-prognosis subgroup but not asmarked as
for patients with a BRAFmutation or microsatellite instability-
high tumor.
These data are consistent with the finding that during the
registration period of FOCUS4, 33% of patients in the RAS/
TP53-mut population experienced progression during the
first 16 weeks of chemotherapy. This is similar to the rate in
the BRAF-mutant group (34% progressed) but higher than
that seen in RAS-mutant (24%) and all wild-type (22%)
subgroups (Data Supplement).
Effect of RAS and TP53 Mutation Subtypes on
Adavosertib Activity
We observed that patients with KRAS codon 12/13 mu-
tations had a significant benefit from adavosertib (P for
interaction 5 .014; Fig 3), whereas no detectable benefit
was observed in those with KRASmutations at other codons
or withNRASmutation. Furthermore, the interaction effects
of KRAS subtype and of PTL on PFS may be additive as







Mean (SD) age, years 61.9 (12.2) 59.2 (12.8)
No. (%) No. (%)
Sex
Male 15 (60) 31 (70)
Female 10 (40) 13 (30)
Current WHO performance status
0 17 (68) 35 (80)
1 8 (32) 9 (20)
Site of primary tumor
Right colon 9 (36) 13 (30)
Left colon 6 (24) 13 (30)
Rectum 10 (40) 18 (41)
Current state of primary tumor
Resected primary 9 (36) 23 (52)
Unresected primary 16 (64) 19 (43)
Unresected local recurrence 0 (0) 2 (5)
Timing of metastases
Metachronous 4 (16) 13 (30)
Synchronous 21 (84) 31 (70)
No. of metastatic sites
One 6 (24) 16 (36)
Two or more 19 (76) 28 (64)
Disease assessment at end of first-line
treatment
Complete response 0 (0) 1 (2)
Partial response 13 (52) 26 (59)
Stable disease 12 (48) 17 (39)
First-line treatment regimen
FOLFOX 7 (28) 15 (34)
FOLFIRI 8 (32) 14 (32)
CAPOX 6 (24) 11 (25)
FOLFOXIRI 3 (12) 3 (7)
Others 1 (4) 1 (2)
PIK3CA mutation status
Mutation 1 (4) 1 (2)
Wildtype 24 (96) 43 (98)
Total 25 (100) 44 (100)
Abbreviations: CAPOX, capecitabine and oxaliplatin; FOLFIRI, fluorouracil, leucovorin,
and irinotecan; FOLFOX, infusional fluorouracil, leucovorin, and oxaliplatin; FOLFOXIRI,
folinic acid, fluorouracil, oxaliplatin, and irinotecan; SD, standard deviation.
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there is a significant benefit from adavosertib within the
subgroup of left PTL KRAS codon 12/13 subtypes
(HR 5 0.16; 95% CI, 0.05 to 0.50) and a clear disbenefit
within the subgroup of right PTL noncodon 12/13 subtypes
(HR5 1.56; 95% CI, 0.49 to 4.97; Data Supplement). The
subtype of TP53 mutation or the co-occurrence of PIK3CA
mutation did not affect outcome.
Toxicity and Compliance
There was good compliance with randomized allocation,
and adavosertib was generally well-tolerated (Fig 5 and
Data Supplement). Compared with AM, adavosertib was
associated with increased reported toxicity ($ grade 1),
most notably increased frequency of diarrhea (61% v
28%), fatigue (75% v 56%), nausea (68% v 32%), and
vomiting (41% v 4%). However, the majority of such
toxicity was of low grade, with 9% in the adavosertib arm
reporting diarrhea of$ grade 3, 11% fatigue, 5% nausea,
and 2% vomiting, versus none of each in the AM arm. As
described, during the trial, there was an increase in the
dose of adavosertib from 250 mg to 300 mg. The higher
dose was associated with an increased frequency of grade
3 diarrhea (14% v 4%), but otherwise the toxicity profile
was similar, and with similar rates of dose modifications
and delays.
Impact of Adavosertib Dosing
As described, during the trial, there was an increase in the
dose of adavosertib from 250 mg to 300 mg. PFS was 2.2
months (HR5 0.58; 95%CI, 0.31 to 1.06) with the 250-mg
dose and 3.7 months (HR 5 0.47; 95% CI, 0.25 to 0.89)
with the 300-mg dose; this difference was nonsignificant
(P 5 .48; Data Supplement). Between the 250-mg and
300-mg doses, there was an increased frequency of grade
3 diarrhea (4% v 14%), but otherwise the toxicity profile
was similar. There were similar rates of dose modifications
between the 250-mg and 300-mg doses: dose delays (16%
v 7%), dose reductions (4% v 5%), and dose omissions
(19% v 17%). A swimmer plot integrating the effects of
adavosertib dose, randomized group, and PTL on PFS is
shown in the Data Supplement.
DISCUSSION
Here, we have reported that FOCUS4-C met its primary end
point; patients with RAS/TP53-mutant mCRC had PFS
advantage with adavosertib compared with AM following
induction chemotherapy. These results are particularly
encouraging as RAS/TP53-mutant mCRC is a poor prog-
nostic population with limited treatment options. Adavo-
sertib was well-tolerated at both doses evaluated.
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FIG 2. (A) PFS (primary analysis) in PPA population: Cox regression, adjusted for minimization factors—HR 5 0.35 (95% CI, 0.18 to 0.68),
P 5 .0022. Minimization factors: location of primary tumor (left, right, and rectum), baseline WHO performance status, baseline disease as-
sessment, number of metastases, and first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody). (B) OS (secondary
analysis) in PPA population: Cox regression, adjusted for minimization factors—HR5 0.86 (95% CI, 0.39 to 1.86), P5 .70. Minimization factors:
location of primary tumor (left, right, and rectum), baseline WHO performance status, baseline disease assessment, number of metastases, and
first-line therapy (fluoropyrimidine, oxaliplatin or irinotecan, and monoclonal antibody). AM, active monitoring; HR, hazard ratio; OS, overall
survival; PFS, progression-free survival; PPA, per-protocol analysis.
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The overarching aim of the FOCUS4 trial program was to
test novel agents efficiently with specified biomarker sub-
groups in mCRC with the multi-arm, multi-stage design
allowing for an early signal of drug inactivity14; thus, any
demonstrated efficacy would require further confirmatory
study to lead to practice change. FOCUS4-C represents
a success of this approach, efficiently demonstrating
promising activity of adavosertib within patients with RAS/
P53-mutant mCRC, and will directly influence research
practice in mCRC.
Overall (unadjusted)
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0.30 (0.05 to 1.84)
0.34 (0.12 to 1.00)
0.16 (0.05 to 0.50)
1.02 (0.41 to 2.56)
0.24 (0.11 to 0.51)
0.81 (0.39 to 1.67)
0.19 (0.07 to 0.50)
0.71 (0.04 to 11.79)
0.42 (0.17 to 1.02)
0.56 (0.27 to 1.18)
0.37 (0.19 to 0.69)
0.75 (0.16 to 3.50)
0.21 (0.02 to 1.88)
0.71 (0.23 to 2.16)
0.50 (0.19 to 1.31)
0.33 (0.11 to 0.99)
0.35 (0.17 to 0.72)
0.84 (0.29 to 2.40)
0.63 (0.28 to 1.38)
0.31 (0.14 to 0.70)
0.33 (0.10 to 1.16)
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FIG 3. Subgroup analyses for PFS by intention to treat. CAPOX, capecitabine and oxaliplatin; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFOX,
infusional fluorouracil, leucovorin, and oxaliplatin; PFS, progression-free survival; PTL, primary tumor location.
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The intermittent treatment strategy used in FOCUS4 follows the
demonstration of no detriment in OS in the MRC COIN trial.
This is now further substantiated by an individual participant
data meta-analysis.16 Thus, AM is an accepted standard of
care following a few months of first-line therapy. FOCUS4 was
specifically designed to use this window following first-line
induction chemotherapy to test novel agents in specified
biomarker groups, before the evolution of multiple resistance
mechanisms.14
A prespecified analysis demonstrated that adavosertib
activity was limited to left colon and rectal PTL, with little
activity observed in right PTL. Having observed the sig-
nificant subgroup effects on PFS, we investigated possible
impact on OS. It is provocative to see that in the left-sided
tumors, OS was significantly improved with median OS from
random assignment increasing from 11.3 months to 14.1
months (HR 5 0.40; 95% CI, 0.17 to 0.97). There is also
a possibility of adverse effect on outcome in patients with
right PTL. However, the number of patients and events was
limited and thus, any conclusions need to be cautious in
relation to this observed effect on OS in both subgroups.
Differences in CRC by PTL are well-documented, in terms
of biology, prognosis, and treatment response,17 but the
mechanisms for differences of treatment efficacy by PTL
are not well-understood.
An exploratory analysis showed that adavosertib had the
most PFS effect in patients with KRAS codons 12/13/TP53-
mutant tumors, with lesser activity in those with extended
KRAS, or NRAS mutations; functional differences between
RAS isoforms are documented.18 Despite the small sample
sizes in FOCUS4-C, the PTL and RAS subtypes subgroup
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FIG 4. Prognostic impact of biomarker subgroups on OS in previous FOCUS trial. HR, hazard ratio; MSI-H,
microsatellite instability-high; OS, overall survival.
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Although these subgroup analyses provide provocative
results, we lack a mechanistic explanation for these dif-
ferences in adavosertib effect; ongoing translational work
shall investigate this. We would recommend that further
clinical development of adavosertib in the RAS/TP53-mut
mCRC population should not be limited by PTL or RAS
subtype but should include close monitoring of patients
with right PTL and extended RAS mutations to ensure that
neither futility nor detriment are observed.
Although the clinical implications of the RAS/TP53 muta-
tion in mCRC are not well-studied, each alteration is in-
dividually well-characterized. Here, we have shown that the
double RAS/TP53-mutant subgroup carries a moderately
poor prognosis (Fig 4) and appears to confer a worse
prognosis than either mutation in isolation. This biomarker
subgroup has thus shown distinct prognostic and therapeutic
relevance and so merits further study in translational work,
existing data sets, and ongoing therapeutic trials in mCRC.
Adavosertib has demonstrated an acceptable safety profile;
the main toxicity was diarrhea. Efficacy was noted at both
the 250-mg and 300-mg doses, with a suggestion of ad-
ditional activity with the higher dose. We would therefore
recommend the 300-mg dosing to progress to further
clinical studies in fit patients. However, in the treatment-
refractory setting, the 250-mg dose may be more tolerable.
There are limitations to this study. We considered, and
would have preferred, a placebo-controlled design; how-
ever, at the time of launching FOCUS4-C, high rates of
nausea and vomiting had been observed in other adavo-
sertib trials and high-dose steroid antiemetics were con-
sidered necessary. For this reason, both clinicians and
patient representatives considered a placebo design un-
feasible. Given the favorable safety data for single-agent
adavosertib in FOCUS4-C, placebo-controlled design could
be considered in the future. It is possible therefore that the
PFS effect observed was influenced by investigator and
patient preference to restart first-line chemotherapy sooner
in the AM arm. However, a marked difference in effect was
observed between the right and left PTL groups treated with
adavosertib, suggesting a lesser effect on the primary
analysis because of this potential bias. Additionally, the PFS
end point was not centrally reviewed, but assessed in in-
dividual sites by RECIST criteria. A further limitation is that
by testing adavosertib in the maintenance setting and re-
quiring stability following induction chemotherapy, we have
excluded the RAS/TP53 patients with the worse outcome.
We therefore cannot generalize the effect of adavosertib
within this entire biomarker group.
In conclusion, adavosertib (AZD1775) has demonstrated
promising activity compared with AM in patients with RAS/
TP53-mut mCRC. This treatment benefit may relate to PTL
and KRAS subtype. Given this clear demonstration of ef-
ficacy in an RCT and acceptable toxicity profile, future
clinical development of adavosertib is warranted particu-
larly as it may represent a future treatment opportunity in
this sizable population of unmet need.







































































































FIG 5. Cumulative reported toxicity, within FOCUS4-C treatment groups and with initial AZD1775 doses separated: (A) active monitoring (n 5 25), (B)
AZD1775 250 mg (n 5 23), and (C) AZD1775 300 mg (n 5 21). G, grade; PPE, palmar plantar erythema.
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